ATACR & SEECR: Tumour-Activated T-Cell Engagers Designed to Drive Potent Synthetic Anti-Tumour Immunity
- Unlock the potential of masked TCEs with Xilio’s tumor-activation platform, designed to deliver potent, localised T cell activation while minimising systemic toxicities and widening the therapeutic index
- Explore next-generation ATACR bispecifics with masked CD3 domains and SEECR tri-specifics incorporating co-stimulatory signaling engineered to enhance T cell potency, persistence, and anti-tumor activity
- Gain insights into Xilio’s pipeline of wholly-owned masked TCE programs targeting PSMA, CLDN18.2, and STEAP1, advancing toward clinical translation across solid tumor indication